Table 5 Partial correlations between changes in Weight gain (ΔWeight%) and changes in HRV measurements controlling for olanzapine dose and PANSS reduction rate

From: Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis

Group

 

ΔSDNN (ms)

ΔLFn

ΔHFn

ΔLF/HF

SCZ (n = 83)

r-value

−0.534

0.437

−0.646

0.452

 

P-value

0.000

0.000

0.000

0.000

EWG (n = 25)

r-value

−0.546

0.352

−0.555

0.558

 

P-value

0.007

0.099

0.006

0.006

NWG (n = 58)

r-value

−0.250

0.054

−0.241

0.021

 

P-value

0.063

0.694

0.074

0.878

  1. ΔSDNN: average change of the standard deviation for the NN interval; ΔLFn: average change of normalized low frequency power; ΔHFn: average change of normalized high frequency power; ΔLF/HF: average change of LF to HF ratio.
Back to article page